IBA Announces Research Collaboration to Strengthen Evidence on the Value of Proton Therapy
Louvain-la-Neuve, Belgium, June 10, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer, today announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center aimed at advancing health economics evidence generation for proton beam therapy.
Louvain-la-Neuve, Belgium, June 10, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer, today announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center aimed at advancing health economics evidence generation for proton beam therapy.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.